Literature DB >> 24150523

Overexpression of microRNA-183 in human colorectal cancer and its clinical significance.

Tong Zhou1, Guang-Jun Zhang, He Zhou, Hua-Xu Xiao, Yu Li.   

Abstract

AIM: MicroRNA-183 (miR-183) has been shown to play a potential oncogenic role in colon cancer. The aim of this study was to evaluate the expression of miR-183 in colorectal cancer (CRC) and its potential relevance to clinicopathological characteristics and patient survival.
MATERIALS AND METHODS: Surgical specimens of cancer tissue and adjacent normal mucosa were obtained from 94 patients with CRC. The relative expression levels of miR-183 in the cancer and the normal adjacent mucosa were measured by quantitative real-time PCR. We analyzed their correlation with clinicopathological parameters and prognostic value.
RESULTS: The relative expression levels of miR-183 were significantly higher in CRC tissues than in the normal adjacent mucosa (P<0.001), and a high expression of miR-183 correlated with advanced clinical stage (P=0.030), lymph node metastasis (P=0.012), and distant metastasis (P=0.049). Kaplan-Meier analysis indicated that patients with high miR-183 expression had a poor overall survival (P=0.002). Moreover, multivariate analysis showed that increased expression of miR-183 was an independent predictor of overall survival.
CONCLUSION: The increased expression of miR-183 is closely related to advanced clinical stage, lymph node and distant metastases, and poor prognosis of CRC, indicating that miR-183 may serve as a predictive biomarker for the prognosis or the aggressiveness of CRC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24150523     DOI: 10.1097/MEG.0000000000000002

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  35 in total

1.  miR-183 and miR-21 expression as biomarkers of progression and survival in tongue carcinoma patients.

Authors:  Gordana Supic; Katarina Zeljic; Aleksandra Divac Rankov; Ruzica Kozomara; Aleksandra Nikolic; Dragica Radojkovic; Zvonko Magic
Journal:  Clin Oral Investig       Date:  2017-06-14       Impact factor: 3.573

2.  Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer.

Authors:  Dawei Yuan; Kang Li; Kun Zhu; Rong Yan; Chengxue Dang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

3.  Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma.

Authors:  Yisila Mu; Haoshaqiang Zhang; Lixin Che; Kun Li
Journal:  Med Oncol       Date:  2013-12-19       Impact factor: 3.064

4.  DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up.

Authors:  Elisabetta Bigagli; Carlotta De Filippo; Cinzia Castagnini; Simona Toti; Francesco Acquadro; Francesco Giudici; Marilena Fazi; Piero Dolara; Luca Messerini; Francesco Tonelli; Cristina Luceri
Journal:  Cell Oncol (Dordr)       Date:  2016-10-05       Impact factor: 6.730

5.  miR-429 mediates tumor growth and metastasis in colorectal cancer.

Authors:  Yantao Han; Qian Zhao; Jie Zhou; Rui Shi
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

6.  An 11-nt sequence polymorphism at the 3'UTR of human SFTPA1 and SFTPA2 gene variants differentially affect gene expression levels and miRNA regulation in cell culture.

Authors:  Patricia Silveyra; Susan L DiAngelo; Joanna Floros
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-05-02       Impact factor: 5.464

7.  Wnt/catenin β1/microRNA 183 predicts recurrence and prognosis of patients with colorectal cancer.

Authors:  Yuzhuo Chen; Weiliang Song
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

8.  MicroRNA 211 expression is upregulated and associated with poor prognosis in colorectal cancer: a case-control study.

Authors:  Ahmet Taner Sümbül; Bülent Göğebakan; Süleyman Bayram; Celal Yücel Batmacı; Serdar Öztuzcu
Journal:  Tumour Biol       Date:  2015-07-08

9.  MicroRNA-496 suppresses tumor cell proliferation by targeting BDNF in osteosarcoma.

Authors:  Jing Ye; Wei Xie; Yunzhou Zuo; Guangwu Jing; Jie Tong
Journal:  Exp Ther Med       Date:  2019-12-19       Impact factor: 2.447

Review 10.  An update on microRNAs as colorectal cancer biomarkers: where are we and what's next?

Authors:  Yoshinaga Okugawa; Yuji Toiyama; Ajay Goel
Journal:  Expert Rev Mol Diagn       Date:  2014-08-28       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.